ARROWHEAD PHARMACEUTICALS IN (ARWR) Fundamental Analysis & Valuation

NASDAQ:ARWR • US04280A1007

Current stock price

56.67 USD
+0.34 (+0.6%)
At close:
56.67 USD
0 (0%)
After Hours:

This ARWR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ARWR Profitability Analysis

1.1 Basic Checks

  • ARWR had positive earnings in the past year.
  • In the past year ARWR had a positive cash flow from operations.
  • ARWR had negative earnings in each of the past 5 years.
  • In multiple years ARWR reported negative operating cash flow during the last 5 years.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • The Return On Assets of ARWR (12.61%) is better than 94.41% of its industry peers.
  • The Return On Equity of ARWR (35.58%) is better than 97.50% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 13.98%, ARWR belongs to the top of the industry, outperforming 95.76% of the companies in the same industry.
Industry RankSector Rank
ROA 12.61%
ROE 35.58%
ROIC 13.98%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • ARWR's Profit Margin of 18.54% is amongst the best of the industry. ARWR outperforms 92.87% of its industry peers.
  • ARWR has a Operating Margin of 27.55%. This is amongst the best in the industry. ARWR outperforms 95.38% of its industry peers.
Industry RankSector Rank
OM 27.55%
PM (TTM) 18.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ARWR Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ARWR is still creating some value.
  • ARWR has more shares outstanding than it did 1 year ago.
  • ARWR has more shares outstanding than it did 5 years ago.
  • ARWR has a better debt/assets ratio than last year.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ARWR has an Altman-Z score of 5.09. This indicates that ARWR is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ARWR (5.09) is better than 74.57% of its industry peers.
  • ARWR has a debt to FCF ratio of 1.80. This is a very positive value and a sign of high solvency as it would only need 1.80 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.80, ARWR belongs to the top of the industry, outperforming 93.64% of the companies in the same industry.
  • ARWR has a Debt/Equity ratio of 0.95. This is a neutral value indicating ARWR is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.95, ARWR is doing worse than 74.18% of the companies in the same industry.
  • Although ARWR's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 1.8
Altman-Z 5.09
ROIC/WACC1.58
WACC8.82%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • A Current Ratio of 3.38 indicates that ARWR has no problem at all paying its short term obligations.
  • The Current ratio of ARWR (3.38) is comparable to the rest of the industry.
  • ARWR has a Quick Ratio of 3.38. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
  • ARWR has a Quick ratio (3.38) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.38
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ARWR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 129.65% over the past year.
  • The Revenue has grown by 43539.24% in the past year. This is a very strong growth!
  • ARWR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 56.63% yearly.
EPS 1Y (TTM)129.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.83%
Revenue 1Y (TTM)43539.24%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%10461.32%

3.2 Future

  • Based on estimates for the next years, ARWR will show a very strong growth in Earnings Per Share. The EPS will grow by 101.11% on average per year.
  • ARWR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.62% yearly.
EPS Next Y-4212.69%
EPS Next 2Y-632.02%
EPS Next 3Y-236.93%
EPS Next 5Y101.11%
Revenue Next Year-40.85%
Revenue Next 2Y-35.09%
Revenue Next 3Y-10.77%
Revenue Next 5Y14.62%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. ARWR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 37.04, which means the current valuation is very expensive for ARWR.
  • ARWR's Price/Earnings ratio is rather cheap when compared to the industry. ARWR is cheaper than 91.33% of the companies in the same industry.
  • ARWR's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.54.
  • The Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 37.04
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ARWR is valued cheaper than 92.68% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ARWR is valued cheaper than 94.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.64
EV/EBITDA 20.99
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • ARWR's earnings are expected to decrease with -236.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-632.02%
EPS Next 3Y-236.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARWR Dividend Analysis

5.1 Amount

  • No dividends for ARWR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARWR Fundamentals: All Metrics, Ratios and Statistics

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (3/23/2026, 8:00:01 PM)

After market: 56.67 0 (0%)

56.67

+0.34 (+0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-05
Earnings (Next)05-11
Inst Owners84.19%
Inst Owner Change3.88%
Ins Owners3.67%
Ins Owner Change-0.46%
Market Cap7.94B
Revenue(TTM)1.09B
Net Income(TTM)202.26M
Analysts80
Price Target81.43 (43.69%)
Short Float %8.27%
Short Ratio3.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.98%
Min EPS beat(2)-14.75%
Max EPS beat(2)26.7%
EPS beat(4)2
Avg EPS beat(4)363.28%
Min EPS beat(4)-20.51%
Max EPS beat(4)1461.66%
EPS beat(8)2
Avg EPS beat(8)69.08%
EPS beat(12)3
Avg EPS beat(12)46.94%
EPS beat(16)4
Avg EPS beat(16)35.01%
Revenue beat(2)1
Avg Revenue beat(2)19.41%
Min Revenue beat(2)-4.15%
Max Revenue beat(2)42.98%
Revenue beat(4)3
Avg Revenue beat(4)433.43%
Min Revenue beat(4)-4.15%
Max Revenue beat(4)1680.09%
Revenue beat(8)3
Avg Revenue beat(8)167.14%
Revenue beat(12)4
Avg Revenue beat(12)110.57%
Revenue beat(16)5
Avg Revenue beat(16)76.26%
PT rev (1m)-0.59%
PT rev (3m)37.46%
EPS NQ rev (1m)-1.8%
EPS NQ rev (3m)-6.88%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)-4.94%
Revenue NQ rev (1m)2.73%
Revenue NQ rev (3m)7.98%
Revenue NY rev (1m)12.16%
Revenue NY rev (3m)15.73%
Valuation
Industry RankSector Rank
PE 37.04
Fwd PE N/A
P/S 7.27
P/FCF 24.64
P/OCF 23.39
P/B 13.96
P/tB 14.12
EV/EBITDA 20.99
EPS(TTM)1.53
EY2.7%
EPS(NY)-4.29
Fwd EYN/A
FCF(TTM)2.3
FCFY4.06%
OCF(TTM)2.42
OCFY4.28%
SpS7.79
BVpS4.06
TBVpS4.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.82
Profitability
Industry RankSector Rank
ROA 12.61%
ROE 35.58%
ROCE 23.92%
ROIC 13.98%
ROICexc 51.35%
ROICexgc 52.33%
OM 27.55%
PM (TTM) 18.54%
GM N/A
FCFM 29.52%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 1.8
Debt/EBITDA 1.65
Cap/Depr 68.96%
Cap/Sales 1.59%
Interest Coverage 250
Cash Conversion 104.19%
Profit Quality 159.2%
Current Ratio 3.38
Quick Ratio 3.38
Altman-Z 5.09
F-Score7
WACC8.82%
ROIC/WACC1.58
Cap/Depr(3y)756.37%
Cap/Depr(5y)612.23%
Cap/Sales(3y)1353.35%
Cap/Sales(5y)819.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.83%
EPS Next Y-4212.69%
EPS Next 2Y-632.02%
EPS Next 3Y-236.93%
EPS Next 5Y101.11%
Revenue 1Y (TTM)43539.24%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%10461.32%
Revenue Next Year-40.85%
Revenue Next 2Y-35.09%
Revenue Next 3Y-10.77%
Revenue Next 5Y14.62%
EBIT growth 1Y148.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-477.94%
EBIT Next 3Y-105.85%
EBIT Next 5Y49.99%
FCF growth 1Y179.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y272.91%
OCF growth 3YN/A
OCF growth 5YN/A

ARROWHEAD PHARMACEUTICALS IN / ARWR Fundamental Analysis FAQ

What is the fundamental rating for ARWR stock?

ChartMill assigns a fundamental rating of 5 / 10 to ARWR.


What is the valuation status of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

ChartMill assigns a valuation rating of 3 / 10 to ARROWHEAD PHARMACEUTICALS IN (ARWR). This can be considered as Overvalued.


What is the profitability of ARWR stock?

ARROWHEAD PHARMACEUTICALS IN (ARWR) has a profitability rating of 5 / 10.


How financially healthy is ARROWHEAD PHARMACEUTICALS IN?

The financial health rating of ARROWHEAD PHARMACEUTICALS IN (ARWR) is 7 / 10.


Can you provide the expected EPS growth for ARWR stock?

The Earnings per Share (EPS) of ARROWHEAD PHARMACEUTICALS IN (ARWR) is expected to decline by -4212.69% in the next year.